A global analysis of over 60,000 RSV sequences indicates that viral variants resistant to current preventive antibodies are rare.
Key facts
- •Researchers analyzed over 60,000 RSV sequences from public databases, covering both RSV A and RSV B subtypes.
- •The study estimates that less than 1% of RSV sequences currently contain resistance mutations.
- •Deep mutational scanning was used to measure the effect of thousands of potential mutations on antibody neutralization.
- •The research team integrated their findings into the open-access pathogen monitoring platform Nextstrain.
- •The analysis specifically examined the effectiveness of the antibodies nirsevimab and clesirovimab.
A study published in Nature reports that viral variants associated with resistance to current respiratory syncytial virus (RSV) prevention tools remain rare. Researchers analyzed more than 60,000 RSV sequences from across the globe to assess the effectiveness of monoclonal antibodies and vaccines. The findings suggest that current prevention methods, which protect infants and vulnerable populations from severe infection, remain highly effective.
By the numbers
Monitoring Viral Resistance
To monitor for potential viral adaptation, researchers utilized a method called deep mutational scanning to create a library of possible RSV mutations. This technique allows scientists to systematically characterize how mutations to the RSV fusion protein affect antibody neutralization without needing to passage the actual virus in a lab setting. By combining these measurements with biophysical modeling and natural sequence analysis, the team evaluated the potential for the virus to evade existing biological blockades. The study, led by researchers at Fred Hutch Cancer Center, integrated these mutation libraries into Nextstrain, an open-access platform. This integration is intended to support real-time surveillance of RSV, allowing scientists to track whether resistant strains emerge or increase in prevalence over time.
Clinical Implications for Prevention
Current RSV prevention strategies include monoclonal antibodies for infants and vaccines for adults, including those administered during the third trimester of pregnancy to provide passive immunity to the fetus. According to lead author Cassandra Simonich, the study found no evidence of sustained spread of resistance mutations for the antibodies nirsevimab and clesirovimab. Simonich estimates that fewer than 1% of the analyzed RSV sequences contain mutations associated with resistance. These tools are particularly vital for infants, older adults with weakened immune systems, and immunocompromised individuals. The researchers emphasize that these findings support the continued use of current prevention methods while providing a framework to guide the development of future strategies.
Advertisement
This article was independently rewritten by ManyPress editorial AI from reporting originally published by Medical Xpress.
